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ABSTRACT: Trans-Pacific Partnership Agreement (TPPA) which is now known as the Comprehensive and Progressive 
Agreement on Trans Pacific Partnership (CP-TPP) opens door of opportunities as well as challenges to Malaysia. The 
agreement has become subject of heated debate in Malaysia as well as other countries due to the reason that it may bring 
some new elements which are not in the other earlier Free Trade Agreements (FTA) on which Malaysia has signed. One of 
the key concern is the possibility of including WTO-Plus commitments in the agreement which is TRIPS-Plus element which 
may affect access to medicine and the local pharmaceutical industry. This study focuses on one issue that is on the potential 
impact of TRIPS-Plus provisions in the intellectual property chapter on Malaysia’s pharmaceutical domestic industry sales. 
In assessing the potential impact of the TPPA on Malaysia’s pharmaceutical industry, simulation exercise using Model of 
Impact Changes in Intellectual Property Rights have been undertaken. The finding of the study indicates that domestic 
pharmaceutical industry sales may drop if data exclusivity, patent term restoration and patent linkage is being implemented.  
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1.  NTRODUCTION 
The Trans-Pacific Partnership Agreement (TPPA) that 
was finally concluded on 5th October 2015 is viewed by 
some as a strategic step towards achieving high income 
nation status by 2020. TPPA is ambitious and 
comprehensive trade agreement and there has been a 
lot of controversy and debate on this mega-trade deal. 
Some argue that the TPPA is more geopolitically 
motivated and that there is no much economic 
advantage that can be gained from the deal while some 
other suggest the potential benefits that Malaysia would 
gain from TPPA will outweighs its costs. The 
proponents argue that the free trade agreement 
between countries across the three continents would 
create a deeper integration and obtain greater market 
access in the TPPA member nations, as well as to serve 
as a stepping stone in penetrating the Latin American 
market. 
The issue on the effect of the TPPA on access to 
affordable medicines in Malaysia is among the most 
contentious one. The TRIPS-plus elements if included in 
the recent agreement on intellectual chapter are 
believed to bring adverse effects to medicine prices, 
medicine expenditure and domestic pharmaceutical 
industry sales. Patent linkages, patent term restoration 
and data exclusivity are among the subject of heated 
debate in the media.  
This study intends to analyze one of the sector that 
might be affected which is the pharmaceutical industry. 
In addition, this study is being conducted to fill in the 
gaps in the literature as there is limited study has been 
undertaken to date. In assessing the potential impact of 
the TPPA on Malaysia’s domestic pharmaceutical 
industry, simulation exercise using Model of Impact 
Changes in Intellectual Property Rights have been 
undertaken. 
 
2. LITERATURE REVIEW 
The reform in intellectual property chapter of the FTA is 
expected to cause innovation due to the protection given to 
inventors. The TRIPS-Plus elements in the FTA agreements 
lead to the strengthening of intellectual property protection. 
TRIPS-Plus Agreement is a higher level of protection than 
the TRIPS Agreement normally negotiated by developed 
nations in their recent FTA negotiation. In TRIPS-Plus 
agreement, signatory countries are normally required to sign 
nine international treaties related to intellectual property, to 
implement provisions like data exclusivity, extension of 
copyright term of protection, patent term restoration, 
patenting of diagnostic, therapeutic and surgical methods, 
patent linkage, compulsory licensing and certain other 
copyright provisions in the intellectual property chapter. 
These provisions are not found in the existing TRIPS 
agreement. Strengthening intellectual property protection is 
expected to benefit drug innovators.  
Elements in TRIPS-Plus such as drug exclusivity, would 
give assurance to the manufacturer of originator’s product 
that they will be granted protection period for their effort in 
inventing or drug testing. Patent linkages will prevent the 
entry of infringing medicines during the patent term. Patent 
term restoration will give compensation to the patent holder 
for any unnecessary delay in patent or drug registration. All 
this consequently is expected to cause an increase in research 
and development specifically in the development of 
medicines for diseases which might be crucial in developing 
country, makes the availability of new medicines even faster, 
rise in foreign direct investment and technology transfer [1 
and 2]. 
On the other hand, there are many studies which highlight 
the adverse effects that TRIPS-Plus provisions may bring. 
This section highlights some past studies which are related to 
the studies which attempted to assess to the impact of 
TRIPS-Plus provision on medicinal or pharmaceutical 
related areas. Table 1 gives the summary of studies being 
reviewed.  
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Table 1: Studies which attempted to assess to the impact of 
TRIPS-Plus provision on medicinal or pharmaceutical related 
areas. 
Study  Author Results 
The effect of new 
possible patent 
systems under 
TPPA on the cost of 
health care with 
specific reference to 
HIV treatment in 
Vietnam. 
[3] with TRIPS flexibility, 82% of 
HIV patients can have 
antiretroviral (ARV) therapy. 
 
Under TPPA (TRIPS-Plus) it 
is expected only 30% of HIV 
patients who can have access 
to ARVs.  
The effects of patent 
in Australia. 
[4] patent term restoration is 
estimated to increase the 
expenditure for: 
Pharmaceutical Benefit 
Scheme from about AUS$6 
million in 2001 to 2002 period 
to AUS$160 million in 2005 
to 2006 period. The cost 
further increase in 2012-2013 
period where it is about 
AUS$240 million. 
Impact of having 
data exclusivity 
provision on a drug 
called colchicine 
[5] after data exclusivity being 
enacted:  
 
price of colchicine have 
increased by more than 5 times 
in the US. 
Effects of TRIPS-
Plus on access to 
medicines based on 
the proposed US-
Thai FTA 
[6] there will be an increase in 
medicine price index by 32%, 
medicines spending 
and domestic industry would 




TRIPS-Plus on the 
cost of medication 
and accessibility to 
essential medicines 
in Thailand. 
[7] in 2003, the availability of 
generics is expected to save 
104.5% of actual costs and 
53.6% increase in accessibility 
and it is forecasted that 
cumulative potential cost is is 
USD 6.2 million for the first 
year and USD 5,215.8 million 
by the tenth year under market 
exclusivity 




access to generic 
drugs in Guatemala. 
[8]  CAFTA intellectual property 
rules reduced access to some 
generic drugs already on the 
market and create barrier for 
the new entry of generics 
medicine,  
several protected drugs are 
available as generics in the 
United States before generic 
versions are legal in 
Guatemala. Data exclusivity 
caused several medicine prices 
to increase up to 846 %. 
How TRIPS-Plus 
intellectual property 
rules in the US-
Jordan FTA affect 
access to medicines.   
[9]  Since 2001, medicine prices 
increased by 20%. Data 
exclusivity has created barrier 
for 79% of generic medicines 
newly launched by 21 
multinational pharmaceutical 
companies between 2002 and 
mid-2006 and additional 
expenditures for medicines 
worth between USD6.3 
million and USD 22.04 
million without generic 
alternative, due to data 
exclusivity by multinational 
companies. 
Possible impact of 
the US-Peru FTA 
on access to 
medicines due to 
data exclusivity 
provision 
[10] it is expected that 700,000 to 
900,000 people cannot afford 
to buy medicines in the first 
five years to sustain the access 
to medicines, the Peruvians 
need to spend an extra of 
US$34.4 million in the first 
year and household and 
Ministry of Health would have 
to increase their expenditure 
by US$28.9 million and 
US$1.6 million respectively. 
Impact of the EU-
Andean trade 
agreement on access 
to medicines in 
Colombia 
[11] In 2025, data exclusivity and 
supplementary patent 
protection (SPC) policies 
would cause total 
pharmaceutical expenditure to 
rise by US$ 756 million, price 
is also estimated to increase by 
16 % and aggregate medicinal 
consumption is projected to 
drop by 10 %. 
Effects of patent 
term extensions on 
research and 
development and 
drug expenditures in 
Canada. 
[12] Extension of patent terms 
combined with other price 
controls and the retrenchment 
of public prescription drug 
subsidy programs have caused 
spending on research and 
development to increase by 
US$4.4 billion and  
medicine spending to rise by 
$3.9 billion. 
The literature review shows that, TRIPS-Plus has affected 
the access to medicine is some countries. In addition, 
specifically in Thailand, the work of Kessomboon [6] shows 
that domestic industry would incur loss more than USD 3 
million.  
In sum, there is limited study to date which attempted to 
assess the potential impact of TRIPS-Plus on pharmaceutical 
industry in developing country. This study shall fill in the 
gap in the literature.  
3. OBJECTIVE OF STUDY 
The objective of the study is: 
>To analyze the potential effects of three TRIPS-Plus 
provisions (i.e. patent term restoration, patent linkages and 
data exclusivity) on Malaysia’s domestic pharmaceutical 
industry sales. 
 
4. METHODOLOGY OF STUDY 
It is expected that strengthening intellectual property rights 
protection under the TPPA would have 3 key impacts which 
are namely medicine price, pharmaceutical/medicine 
expenditure and domestic pharmaceutical industry sales. Only 
the impact on domestic pharmaceutical industry sales is 
estimated in this study using a scenario model method based 
on the Macroeconomic Model of Impact Changes in 
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Intellectual Property Rights (MICIPR) developed by Rovira 
[1, 2, 6 and 13]. The MICIPR has been used in different 
contexts to various countries like Colombia, Guatemala, 
Costa Rica, Bolivia, Costa Rica, the Dominican Republic [6], 
Uruguay and Argentina [15] and Thailand [6]. 
Changes in IPR may cause changes in the degree of competition. 
As monopoly power increases, the price may also change. Hence, 
if stronger IP protection is implemented, it may cause price to rise. 
Increase in price will eventually lead to the increase in 
pharmaceutical expenditure.  
The estimated impact using MICIPR is based on comparison 
between the present intellectual property rights (IPR) regime and 
the possible IPR regime under the TPPA. The principle underlying 
the model is to compare baseline and alternative scenarios. The 
baseline scenario or current scenario indicates the IPR condition in 
Malaysia under TRIPS regime while alternative scenario is the 
possible/expected IPR provision under the TPPA.  
It is important to note that the possible/expected IPR provisions 
assumed here are not necessarily the true IPR provisions under 
actual TPPA or CP-TPP since there are provisions or elements that 
might be suspended. The study takes into account 3 provisions of 
the IP chapter that are directly related to pharmaceutical industry. 
Considering that in the model, given both the current and 
alternative scenario, the model simulates the effect of TRIPS-plus 
on domestic pharmaceutical industry. 
In this study, MICIPR computes the number of medicines 
registered in the market each year starting from the number of 
medicine registered in 2006. For 2007 onwards, the number 
of medicine is computed by adding the number of medicine 
entering the market and subtracting the number of medicine 
exiting the market. The model also calculates the number of 
medicine with patent-protection exclusivity in the market by 
summing the number of those entering the market with patent 
protection and subtracting the number of medicine that lose 
exclusivity protection every year. The exclusivity period is 
computed by summing the original period of patent 
protection with the additional period granted by the three 
TRIPS-Plus provisions of the FTA.  
Under market exclusivity, total number of medicines under 
exclusivity is the sum of those under patent protection and 
those under new provisions’ protection. It is necessary to 
express and quantify the amendment in the provisions of IPR 
and other pharmaceutical policies in mathematical forms. 
Hence, the quantitative form of expression is used and the 
mathematical equation are not shown here but using the one 
as depicted in Rafiq [2]. 
The three TRIPS-Plus provisions of the FTA that results 
patent term extensions more than 20 years of TRIPS’ 
Agreement are: 
1) plus 10 years compensation as a result of delays in the 
granting of a patent or approval for marketing of the 
medicine [6] 
2) prevent or delay marketing approval of generics for 1 year 
due patent linkages. 
3) additional period of 5 years due to data exclusivity [6] 
The model attempts to assess the impact on domestic 
pharmaceutical industry sales by computing the difference in 
domestic industry market sales under alternative scenario and 
baseline scenario. The equations take into account the 
proportion of market under exclusivity and competition for 
both the baseline and the potential TPPA scenario.  
The bigger the proportion of market under competition in 
current scenario, the larger will be the impact on total 
domestic industry sales as a result of alternative scenario.  
This happens because larger number of people is dependent on 
generics medicine in baseline scenario. As prices increase and 
generics manufacturer are not allowed to sell new generics 
products, people becomes less afford to purchase expensive 
medicines. Hence, sales of domestic pharmaceutical industry 
will drop. 
Seven scenarios are being simulate in this study and they are 
[2]: 
a. Scenario 1: Have patent term restoration provision 
b. Scenario 2: Have patent linkages provision 
c.. Scenario 3: Have data exclusivity provision 
d. Scenario 4: Have patent term restoration and patent linkages 
provision 
e. Scenario 5: Have patent term restoration and data 
exclusivity provision 
f. Scenario 6: Have patent linkages and data exclusivity 
provision 
g. Scenario 7: Worst case scenario (having all 3 provisions) 
To sum up, changes in IPR are expected to cause changes on 
the welfare of society. The effects on welfare can happen in a 
different ways such as changes in price level, expenditure and 
gain/loss to domestic pharmaceutical industry. However, the 
estimated changes in domestic pharmaceutical industry sales 
here take into account only three TRIPS-Plus provisions. 
Other factors not in the model such as changes in energy price 
which may affect price are not taken into account. The details 
of the complete methodology is as depicted in [1, 2]. 
 
5. FINDINGS  
For the impact on domestic pharmaceutical industry, the 
effect differs across various combination of provisions 
imposed and it depends on period of compensation given to 
patent holder. In terms of single provision, it is evident that 
patent term restoration produces the biggest impact on 
domestic medicinal industry as compared to other single 
provision. This is followed by data exclusivity and patent 
linkages.  
By comparing all possible provisions combination, as 
expected, triple provisions (scenario 7) or implementing all 
three provisions produce the most severe impact on 
domestic pharmaceutical industry. This is followed by the 
combination of patent term restoration and data exclusivity 
(scenario 5), the combination of patent term restoration and 
patent linkages (scenario 4), patent term restoration 
provision only (scenario 1), the combination of patent 
linkages and data exclusivity (scenario 6), data exclusivity 
provision only (scenario 1) and patent linkages only 
(scenario 2).  
Figure 1 compares the different potential impacts produced 
by different IP provisions on Malaysia’s domestic medicine 
industry sales. The drop in domestic medicine sales is 
forecasted to continue even after 15 years of 
implementation. Consequently, it results to potential 
budgetary burden on both government and private 
consumers who have to consume some patented originators 
medicine due to delay in the entry of generic medicines. 
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Local generic medicines manufacturers have to wait until 
extra period of protection expires. Additional funds will 
have to be allocated by the government or taken out of 
consumers’ pocket then to meet future needs.The value in 
figure below shows a decline even though a negative sign 
is not shown in the figure.  
 
Figure:  1155 s’apsy la  poptIapmI  Domestic 




6.  DISCUSSION 
All the scenarios are expected to affect medicine access 
adversely. However, it is to be noted many medicines are 
not affected to these possible provisions. This is due to the 
fact that many medicines used widely in the hospitals are off 
patent medicines, hence not affected by those provisions. 
Many medicines which the general public consume have no 
patent protection  
 
7. CONCLUSIONS 
The implementation of TRIPS-Plus may cause domestic 
pharmaceutical industry sales to drop in the future. The 
severity of the impact depends on the years of extra 
protection due to new provisions given to patent holder. The 
longer the compensation period the severe would be the 
impact. The estimation in this study is based on its 
assumption and those mention in the work of Rafiq [13]. 
The idea is to estimate the direction of sales, increase or 
decrease and not really how much on the actual drop.  
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